Repaglinide

Routes
Oral (PO)
Half-Life (t½)
PO: 1h
Formula
C27H36N2O4
Molecular Weight
452.59 g/mol
PubChem CID
65981
Aliases
Prandin

Pharmacological Mechanism

Meglitinide — closes pancreatic β-cell K-ATP channels (same target as sulfonylureas, distinct binding site) → insulin release. Short half-life supports pre-prandial dosing for post-prandial glucose control. Hepatic CYP2C8 + CYP3A4 substrate.

Half-Life & Elimination Curve (PO: 1h)

100%50%25%12.5%0%0h0×t½1h1×t½2h2×t½3h3×t½4h4×t½5h5×t½0×t½ (0h): 100% remaining (~13.9 µg/L)1×t½ (1h): 50% remaining (~6.93 µg/L)2×t½ (2h): 25% remaining (~3.46 µg/L)3×t½ (3h): 12.5% remaining (~1.73 µg/L)4×t½ (4h): 6.3% remaining (~0.866 µg/L)5×t½ (5h): 3.1% remaining (~0.433 µg/L)
Plasma (PO)t½ Decay (1h)
  • 0×t½0h100% (13.9 µg/L)
  • 1×t½1h50% (6.93 µg/L)
  • 2×t½2h25% (3.46 µg/L)
  • 3×t½3h12.5% (1.73 µg/L)
  • 4×t½4h6.3% (0.866 µg/L)
  • 5×t½5h3.1% (0.433 µg/L)
Elimination t½1h (PO)
Rate Constant (ke)0.693 h⁻¹
Time to Peak (Tmax)32m
Est. Peak (Cmax)13.9 µg/L
Clearance (CL)20.8 L/h
97% Washout (5×t½)5h

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References